End Stage Renal Disease (ESRD) Drug Market 2024 | Market Size, Key Drivers, Industry Developments, Share, Future Growth Prospects And Forecast To 2033
Overview and Scope
End stage renal disease (ESRD)
drug is a drug used to treat a medical illness in which a person's kidneys stop
working permanently, requiring a kidney transplant or a regular regimen of
long-term dialysis to protect life. It is crucial in treating and preventing
secondary problems in individuals with chronic renal disease (CKD).
Sizing and Forecast
The end stage renal disease (esrd)
drug market size has grown rapidly in recent years. It will grow from $116.32
billion in 2023 to $132.86 billion in 2024 at a compound annual growth rate
(CAGR) of 14.2%. The growth in the historic period can be
attributed to increasing incidence of end stage renal disease, growing aging
population, improved access to healthcare services, government initiatives and
policies, increasing adoption of renal replacement therapies.
The end stage renal disease (esrd)
drug market size is expected to see rapid growth in the next few years. It will
grow to $232.13 billion in 2028 at a compound annual growth rate (CAGR) of
15.0%. The growth in the forecast period
can be attributed to emerging therapies and drug innovations, increasing
healthcare expenditure, rising global burden of chronic kidney diseases,
personalized medicine approaches, regulatory support and expedited approvals.
Major trends in the forecast period include increasing incidence of end stage
renal disease, advancements in treatment modalities, growing emphasis on
precision medicine, development of combination therapies, technological
integration in healthcare.
To access more details
regarding this report, visit the link:
Segmentation & Regional
Insights
The end stage renal disease (esrd)
drug market covered in this report is segmented –
1) By Product Type:
Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate
Binders, Other Products
2) By Indication: End Stage
Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease
(ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced
Hyperkalaemia
3) By Distribution Channel:
Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals,
Homecare, Specialty Clinics, Other End Users
North America was the largest
region in the end stage renal disease (ESRD) drug market in 2023. The regions
covered in the end stage renal disease (esrd) drug market report are
Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle
East, Africa
Intrigued to explore the
contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Major Driver Impacting Market
Growth
Rising cases of obesity and
diabetes are expected to propel the growth of the end-stage renal disease
(ESRD) drug market going forward. Obesity is described as abnormal or excessive
fat buildup that poses a health concern. In contrast, diabetes is a chronic
condition that happens when the pancreas does not create enough insulin or when
the body cannot utilize the insulin produced efficiently. In patients with
renal disease, managing fluid and electrolyte levels, blood pressure, and waste
product elimination through dialysis can improve general health and well-being,
which may lead to weight reduction and improve blood sugar control. For
instance, in March 2022, according to World Obesity, a US-based membership
organization representing national and regional associations dedicated to the
study and management of obesity, the number of obese people is expected to rise
to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in
September 2021, according to the International Diabetes Federation (IDF), a
Belgium-based umbrella organization of over 230 national diabetes
organizations, approximately 537 million individuals (20–79 years of age) were
living with diabetes in 2021, with this figure expected to rise to 643 million
by 2030 and 783 million by 2045. Therefore, the rising cases of obesity and
diabetes will drive the market for end-stage renal disease (ESRD) drugs.
Key Industry Players
Major companies operating in the
end-stage renal disease (ESRD) drug market are focusing on product approvals
such as Jardiance to drive revenues in their market. Empagliflozin is a drug
intended to help persons with type 2 diabetes and to lower the chance of
cardiovascular issues in persons with type 2 diabetes who have heart failure or
cardiovascular disease. For instance, in September 2023, Boehringer Ingelheim
Pharmaceuticals Inc. a US-based pharmaceutical company received FDA approval
for Jardiance. Jardiance has been approved for a number of indications, such as
lowering the risk of end-stage kidney disease, cardiovascular death, and
hospitalization in adults with chronic kidney disease at risk of progression,
as well as lowering the risk of sustained decline in estimated glomerular
filtration rate (eGFR) in adults with heart failure. Jardiance is a
sodium-glucose cotransporter 2 (SGLT2) inhibitor and is contraindicated in
patients with type 1 diabetes and those with an eGFR less than 20 ml/min/1.73
m.
The end stage renal disease
(esrd) drug market report table of contents includes:
1. Executive Summary
2. End Stage Renal Disease (ESRD)
Drug Market Characteristics
3. End Stage Renal Disease (ESRD)
Drug Market Trends And Strategies
4. End Stage Renal Disease (ESRD)
Drug Market - Macro Economic Scenario
5. Global End Stage Renal Disease
(ESRD) Drug Market Size and Growth
..................................
31. Global End Stage Renal Disease
(ESRD) Drug Market Competitive Benchmarking
32. Global End Stage Renal Disease
(ESRD) Drug Market Competitive Dashboard
33. Key Mergers And Acquisitions
In The End Stage Renal Disease (ESRD) Drug Market
34. End Stage Renal Disease (ESRD)
Drug Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment